Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonya L Heltshe

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Pediatrics|February 2, 2017
Growth in Prepubertal Children With Cystic Fibrosis Treated With IvacaftorMichael S Stalvey, Jesse Pace, Minoo Niknian, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 13, 2024
Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiativeJonathan D Cogen, Sonya L Heltshe, Adam W Brothers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutationsJennifer Guimbellot, George M Solomon, Arthur Baines, et al.
JAMA Pediatrics|April 25, 2017
Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of LifeDaniel H Leung, Sonya L Heltshe, Drucy Borowitz, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 28, 2017
Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn ScreeningDaniel Gelfond, Sonya L Heltshe, Michelle Skalland, et al.
Thorax|April 26, 2015
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosisSonya L Heltshe, Christopher H Goss, Valeria Thompson, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 18, 2022
Association between stool consistency and clinical variables among infants with cystic fibrosis: Findings from the BONUS studyA Jay Freeman, Rong Huang, Sonya L Heltshe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 20, 2022
Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551DJordana E Hoppe, Brandie D Wagner, J Kirk Harris, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 24, 2024
Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosisMinJae Lee, Meghana Sathe, Baha Moshiree, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Pediatrics|February 2, 2017
Growth in Prepubertal Children With Cystic Fibrosis Treated With IvacaftorMichael S Stalvey, Jesse Pace, Minoo Niknian, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 13, 2024
Creation of a CF-specific antibiotic spectrum index (ASI) as an antimicrobial stewardship initiativeJonathan D Cogen, Sonya L Heltshe, Adam W Brothers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutationsJennifer Guimbellot, George M Solomon, Arthur Baines, et al.
JAMA Pediatrics|April 25, 2017
Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of LifeDaniel H Leung, Sonya L Heltshe, Drucy Borowitz, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 28, 2017
Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn ScreeningDaniel Gelfond, Sonya L Heltshe, Michelle Skalland, et al.
Thorax|April 26, 2015
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosisSonya L Heltshe, Christopher H Goss, Valeria Thompson, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 18, 2022
Association between stool consistency and clinical variables among infants with cystic fibrosis: Findings from the BONUS studyA Jay Freeman, Rong Huang, Sonya L Heltshe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 20, 2022
Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551DJordana E Hoppe, Brandie D Wagner, J Kirk Harris, et al.
Contemporary Clinical Trials|November 25, 2017
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CFSonya L Heltshe, Natalie E West, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 24, 2024
Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosisMinJae Lee, Meghana Sathe, Baha Moshiree, et al.
Pageof 10